99
Participants
Start Date
August 31, 2009
Primary Completion Date
April 30, 2010
Study Completion Date
October 31, 2012
Ipilimumab
Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
Memorial Sloan Kettering Cancer Center, New York
St Luke'S Hospital And Health Network, Bethlehem
Carolinas Medical Center, Charlotte
The Angeles Clinic & Research Inst., Los Angeles
California Pacific Medical Center, San Francisco
H Lee Moffitt Cancer Center, Tampa
Seattle Cancer Care Alliance, Seattle
Lead Sponsor
Collaborators (1)
Medarex
INDUSTRY
Bristol-Myers Squibb
INDUSTRY